Baystreet Staff - Monday, June 1, 2015 Exelixis (EXEL) surges on Phase 2 results Exelixis, Inc. (NASDAQ: EXEL) shares rose 8.9% to $3.43 following the announcement of positive Phase 2 cabozantinib results at the ASCO. Share volume was 2.9 million, compared to an all-day average of 3.3 million